[Immunohistological study on ras and myc oncogene products in pancreatic cancer].
Surgical treatment of the pancreatic cancer is currently unsatisfactory. By using anti-K,H,N-ras monoclonal and anti-myc polyclonal antibodies, paraffin-embedded tissue specimens of the carcinoma in digestive organs were immunohistologically studied. Then, the incidence of expression of these oncogenes and correlative studies of survival rate and disease stage of pancreatic cancer were analyzed. High incidence of expression of ras oncogene in the carcinoma of the pancreas and biliary tract was obtained. Frequency of expression of ras oncogene was correlated to disease stage and T factor for staging the carcinoma of the pancreas. Prognoses of 6 cases of pancreatic cancer without expression of ras oncogene were better than that of pancreatic cancer expressed ras oncogene.
Motoshima
K
K
Second Department of Surgery and Oncology, Nagasaki University School of Medicine, Japan.
Kohara
N
N
Shiogama
T
T
Fujii
M
M
Nakago
S
S
Tsunoda
T
T
Nagata
Y
Y
D001661:Biliary Tract Neoplasms / Q000235:genetics; D003110:Colonic Neoplasms / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000235:genetics; D015513:Oncogene Proteins / Q000032:analysis*; D010190:Pancreatic Neoplasms / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D016283:Proto-Oncogene Proteins p21(ras); D013274:Stomach Neoplasms / Q000235:genetics
D015513:Oncogene Proteins; D011518:Proto-Oncogene Proteins; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)